Market News & Trends
CCAB Partners With ImmunoBiochem as it Launches New Co-Development Strategy to Advance Early-Stage Biotech Companies
The Centre for the Commercialization of Antibodies and Biologics (CCAB) and ImmunoBiochem Corporation have announced an agreement that will see CCAB provide a new investment to help advance ImmunoBiochem’s novel breast cancer therapeutic candidate one step closer to the clinic.
Rexahn Pharmaceuticals Announces Clinical Collaboration With Merck
Rexahn Pharmaceuticals, Inc. recently announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC).
Pfizer & Astellas Amend Clinical Research Protocols for Two Phase 3 Trials
Pfizer Inc. and Astellas Pharma Inc. recently announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).
Orchard Therapeutics Announces $150-Million Financing to Advance Pipeline
Orchard Therapeutics recently announced the completion of an oversubscribed $150 million Series C financing. Deerfield Management led the financing with significant new investments from RA…
Stemline Therapeutics Announces FDA Accepts ELZONRIS BLA & Grants Priority Review
Stemline Therapeutics, Inc. recently announced US FDA has accepted for filing the company’s Biologics License Application (BLA) for ELZONRIS (tagraxofusp; SL-401) for the treatment of…
MeiraGTx Announces AAV-CNGA3 Has Received Orphan Drug Designation
MeiraGTx Holdings Plc recently announced that the US FDA has granted orphan drug designation (ODD) for its AAV-CNGA3 gene therapy product candidate for the treatment…
Mustang Bio & St. Jude Children’s Research Hospital Enter Exclusive Worldwide License Agreement
Mustang Bio, Inc. and St. Jude Children’s Research Hospital recently announced they have partnered and entered into an exclusive worldwide license agreement for the development…
CytoDyn Announces Strong Preclinical Results Using PRO 140 in Human Colon Carcinoma
CytoDyn Inc. recently announced that PRO 140 (leronlimab) has been shown effective at inhibiting the growth of a human colon carcinoma cell line (SW480) in…
Aegis Awarded US Patent for Formulation & Non-invasive Delivery of Peptide Drugs
Aegis Therapeutics LLC recently announced it has been awarded US Patent No. 10,046,025, providing non-invasive delivery of cyclic peptide drugs. Cyclic-peptide drugs are an increasingly…
Sol-Gel Technologies Announces Collaborative Agreement With Perrigo
Sol-Gel Technologies Ltd. recently announced it has entered into a collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc, for the development, manufacturing, and commercialization of a generic product candidate.
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial
Clementia Pharmaceuticals Inc.recently announced the early completion of patient enrollment in the MOVE Trial, Clementia’s registrational Phase 3 clinical study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP).
MilliporeSigma & InnoCore Pharmaceuticals to Improve Patient Compliance With New Drug Delivery Technology
MilliporeSigma and InnoCore Pharmaceuticals; Groningen, Netherlands, have recently entered into a global cooperation agreement to provide InnoCore’s proprietary SynBiosys biodegradable polymer platform. The drug delivery…
Aegis’ Expands International & US Intravail Patent Portfolio on Multiple Fronts
Aegis Therapeutics LLC recently announced it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast- acting formulations for triptans, a…
International Stem Cell Corporation Developed 3D Liver Structures
International Stem Cell Corporation recently announced that ISCO’s Research and Development team has developed novel methods that efficiently generate human 3D liver-like tissue. According to…
Innovest Global Signs Worldwide Agreement With Cedars-Sinai Medical Center to Commercialize Vaccine
StemVax Therapeutics, an Innovest Global Inc. holding, has been awarded an exclusive worldwide license agreement from Cedars-Sinai Medical Center in Los Angeles, CA, for all…
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement to Advance AAV Gene Therapy Technology
Fortress Biotech recently announced that its subsidiary, Aevitas Therapeutics, Inc. has entered into a sponsored research agreement (SRA) with the laboratory of Wenchao Song, PhD,…
Therapeutic Solutions International Develops Microemulsion Formulation of Alpha Lipoic Acid for Intranasal Delivery
Therapeutics Solutions International, Inc. recently announced successful production of a stable microemulsion of Alpha Lipoic Acid (ALA) from ingredients Generally Regarded as Safe (GRAS). The…
Nevakar & Endo Enter Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products
Nevakar Inc. recently announced it entered into an exclusive licensing agreement with Endo International plc’s subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the US and Canada.
Credence MedSystems Closes $12.8-Million Financing to Support Ongoing Development & Scaling of Innovative Delivery Products
Credence MedSystems, Inc., an innovator in injectable drug delivery devices, recently announced the closing of a Series B financing resulting in gross proceeds to the company of $12.8 million.
Avalon GloboCare Forms Strategic Partnership With Weill Cornell Medical College to Co-develop Technologies & Bio-production of CAR-T Therapy
This strategic partnership aims to co-develop bio-production and standardization procedures in procurement, storage, processing, clinical study protocols, and bio-banking for Chimeric Antigen Receptor (CAR)-T therapy, in accordance with the Foundation of Accreditation for Cellular Therapy (FACT) and American Association of Blood Banks (AABB) standards.
